ArticleAlzheimer's & dementia (New York, N. Y.)
Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE).
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBlood-based Alzheimer's disease (AD) biomarkers are increasingly used in clinical care, but there are few real-world studies of their clinical utility. We evaluated the impact of plasma phosphorylated tau at threonine 181 (p-tau181) on the diagnosis and management of patients with cognitive impairment in a memory clinic.
methodsDementia specialists referred patients for plasma p-tau181 testing during clinical care. We used surveys and chart review to assess the impact of plasma p-tau181 testing on clinical care and patient and care partner wellbeing. We assessed co-primary outcomes of (1) change in diagnostic confidence before vs after testing, (2) change in diagnosis, and (3) change in management. A diagnosis or management change of greater than 30% was considered to be clinically significant. Secondary and exploratory outcomes included impact of plasma p-tau181 testing on the use of additional diagnostics and impact on patient and care partner psychological wellbeing, health behaviors, and future planning.
resultsOne hundred patients completed plasma p-tau181 testing; 81% had an elevated result, and 19% had a non-elevated result. Clinician diagnostic confidence averaged 1.43 points higher after p-tau181 testing (95% confidence interval [CI] 1.02 to 1.84, DISCUSSION: Non-elevated plasma p-tau181 results impacted the diagnosis and use of amyloid PET imaging in a memory clinic. There was increased anxiety in patients after testing, affirming the need for post-disclosure psychological support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.